Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II trial of erlotinib versus intermittent erlotinib + docetaxel in former male smokers with advanced squamous NSCLC after chemotherapy failure
2010-020229-42Phase 2Completed
- Sponsor
- Roche
- Start
- Jul 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) and Pulmonary squamous cell carcinoma comparing Tarceva monotherapy with Intermittent Tarceva + docetaxel (2 arms). Primary endpoint: Percentage of patients progression-free at 6 months. Started Jul 2010; status: completed.
02
Drugs
erlotinibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2010-020229-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020229-42.